Kyllähän nämä aika rohkaisevia näkemyksiä edustavat:
Dr. Naval Daver, MD, said, “This data with bexmarilimab plus azacitidine is highly encouraging, especially in the r/r MDS setting where treatment options are limited and outcomes remain poor. Seeing promising survival outcomes and overall response rates in patients after HMA failure highlights the potential of this approach. The observed immune activation in the bone marrow further reinforces the mode of action of bexmarilimab and offers hope for bridging patients towards a bone marrow transplant, which could lead to a possible cure.”
Dr. Mika Kontro, Associate Professor at University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology said, “For patients living with high-risk MDS, especially those who have exhausted current treatments, any therapy that offers patients more time and improves hematological parameters is a welcomed development. The continued progress of therapies like bexmarilimab brings much-needed optimism to patients and families navigating this difficult disease.”
Juho Jalkanen, MD, PhD, Chief Executive Officer of Faron Pharmaceuticals, said, “These amazing results reinforce our confidence in bexmarilimab’s potential to transform care for patients with high-risk MDS. This data not only strengthens the rationale for advancing to a randomized Phase III trial in frontline HR-MDS, in line with FDA guidance, but also marks a significant step forward in our clinical development strategy towards approval.”
Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025 - Faron